- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00768391
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
June 27, 2011 updated by: Eli Lilly and Company
Phase I Study of Anti-Platelet Derived Growth Factor Receptor Alpha (PDGFRa) Monoclonal Antibody IMC-3G3 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom no Standard Therapy is Available
The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.
Study Overview
Detailed Description
The purpose of this study is to establish the safety profile and maximum tolerated dose (MTD) of the anti-PDGFRα monoclonal antibody IMC-3G3 in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46282
- ImClone Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- ImClone Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histopathological-documented, measurable, or non measurable, advanced primary tumor or recurrent solid tumor or lymphoma unresponsive to standard therapy or for which there is no standard therapy available.
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry.
- Able to provide written informed consent.
- Age 18 years or older.
- Life expectancy of > 3 months.
- Adequate hematologic function, as defined by: an absolute neutrophil count ≥ 1500/mm3; a platelet count ≥ 100,000/mm3
- Adequate hepatic function, as defined by: a total bilirubin level ≤ 1.5 x the upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2.5 x the ULN or ≤ 5 x the ULN if known liver metastases
- Adequate renal function, as defined by serum creatinine level ≤ 1.5 x the ULN.
- Uses effective contraception (per the institutional standard), if procreative potential exists.
- Adequate recovery from recent surgery, chemotherapy, and radiation therapy.
- Accessible for treatment and follow-up, must be treated at the participating center.
Exclusion Criteria:
- Received chemotherapy or therapeutic radiotherapy 28 days prior to the first dose of study medication or has ongoing side effects ≥ grade 2 due to agents administered more than 28 days earlier.
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring parenteral antibiotics; symptomatic congestive heart failure; unstable angina pectoris, angioplasty, stenting, or myocardial infarction 6 months prior to the first dose of study medication; uncontrolled hypertension; clinically significant cardiac arrhythmia including but not limited to: multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia; uncontrolled diabetes; psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
- Progressive or symptomatic brain metastases
- Has a serious or nonhealing active wound, ulcer, or bone fracture.
- Known human immunodeficiency virus positivity.
- Major surgical procedure, an open biopsy, or a significant traumatic injury 28 days prior to treatment.
- Is currently or has recently used (28 days prior to) a thrombolytic agent.
- Currently using full-dose warfarin (an exception is low-dose warfarin to maintain patency of pre-existing, permanent, indwelling intravenous [I.V.] catheters; for patients receiving warfarin, the international normalized ratio [INR] should be < 1.5). A patient requiring heparin is excluded.
- Undergoes chronic daily treatment with aspirin (> 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function (cyclooxygenase-2 [COX-2] inhibitors are permitted).
- Has a history or clinical evidence of a deep venous or arterial thrombosis (including pulmonary embolism) 6 months prior to the first dose of study medication.
- Has proteinuria ≥ 2+ by routine urinalysis
- Pregnancy (confirmed by serum beta human chorionic gonadotropin) or lactating
- Received prior treatment with agents targeting the PDGFR ligand or receptor 6 weeks prior to the first dose of study medication.
- Received prior treatment with monoclonal antibodies 6 weeks prior to the first dose of study medication.
- Has a history of allergic reactions to monoclonal antibodies or other therapeutic proteins.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMC-3G3
All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
|
Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts.
Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose).
Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of Participants Reporting Adverse Events
Time Frame: Approximately 36 months
|
Approximately 36 months
|
|
Maximum Tolerated Dose (MTD)
Time Frame: Approximately 36 months
|
After all patients complete a cohort, toxicity data is reviewed before the next cohort of patients is treated at the next higher dose level
|
Approximately 36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics
Time Frame: 6 weeks
|
6 weeks
|
Anti-IMC-3G3 Antibody Assessment
Time Frame: Approximately 36 months
|
Approximately 36 months
|
Antitumor Activity of IMC-3G3 as Monotherapy
Time Frame: 6 weeks
|
6 weeks
|
Pharmacodynamics
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: E-mail: ClinicalTrials@ ImClone.com, Eli Lilly and Company
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
January 1, 2010
Study Registration Dates
First Submitted
October 6, 2008
First Submitted That Met QC Criteria
October 7, 2008
First Posted (Estimate)
October 8, 2008
Study Record Updates
Last Update Posted (Estimate)
June 28, 2011
Last Update Submitted That Met QC Criteria
June 27, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13937
- CP15-0601 (Other Identifier: ImClone, LLC)
- I5B-IE-JGDC (Other Identifier: Eli Lilly and Company)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
Clinical Trials on IMC-3G3
-
Eli Lilly and CompanyTerminatedGastrointestinal Stromal Tumor (GIST)United States, Belgium, Germany, Netherlands, Poland, Spain
-
Eli Lilly and CompanyCompletedMetastasis | MalignancyJapan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyCompletedAdult Glioblastoma MultiformeUnited States
-
Aronora, Inc.Completed
-
Eli Lilly and CompanyCompletedSarcoma, Soft TissueUnited States
-
OHSU Knight Cancer InstituteNational Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science...TerminatedMalignant Solid Neoplasm | Lymphoma | Plasma Cell MyelomaUnited States
-
Eli Lilly and CompanyCompleted
-
Aronora, Inc.CompletedThrombosis | End Stage Renal DiseaseUnited States
-
Eli Lilly and CompanyCompletedNon-Small Cell Lung CancerUnited States, Canada
-
Eli Lilly and CompanyCompleted